uric acid has been researched along with Headache in 25 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 9.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "Nifedipine has been used in hypertension, mainly as a third-line drug for rapid blood pressure reduction, for over 10 years." | 9.06 | Is nifedipine a suitable first-line treatment for essential hypertension in general practice? ( Adams-Strump, BJ; Gaw, N; Langan, JJ; Murray, TS; Sullivan, FM, 1987) |
| "Objective To explore the possible correlation between uric acid levels and leukoaraiosis (LA)." | 7.85 | The association of uric acid with leukoaraiosis. ( Cai, RW; Chen, YF; Huang, YH; Li, JJ; Li, MM; Lin, YY, 2017) |
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 5.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| "Nifedipine has been used in hypertension, mainly as a third-line drug for rapid blood pressure reduction, for over 10 years." | 5.06 | Is nifedipine a suitable first-line treatment for essential hypertension in general practice? ( Adams-Strump, BJ; Gaw, N; Langan, JJ; Murray, TS; Sullivan, FM, 1987) |
| "Objective To explore the possible correlation between uric acid levels and leukoaraiosis (LA)." | 3.85 | The association of uric acid with leukoaraiosis. ( Cai, RW; Chen, YF; Huang, YH; Li, JJ; Li, MM; Lin, YY, 2017) |
| " Univariate analysis revealed statistical significance for the following variables associated with eclampsia: systolic hypertension > or =160 mmHg and diastolic > or =110 mmHg, headache, visual symptoms, vivid deep tendon reflexes, proteinuria >3+ or >3 g d(-1), uric acid concentration > or =350 micromol l(-1), serum creatinine concentration >100 micromol l(-1) and aminotransferase aspartate >30 IU l(-1)." | 3.72 | [Risk factors for eclampsia: a case-control study]. ( Arfaoui, C; Ben Salem, F; Ben Salem, K; Faleh, R; Gahbiche, M; Grati, L; Guerdelly, I; Jmel, A, 2003) |
| "Univariate analysis revealed statistical significance for the following variables associated with eclampsia: uric acid concentration, > 8." | 3.70 | Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. ( Mattar, F; Saade, GR; Sibai, BM; Witlin, AG, 1999) |
| "In this study we aimed at evaluating the modifications in the pharmacokinetic profile of cyclosporin A (CyA) after conversion from standard formulation (CyA-ST) to a new formulation (CyA-NF, Sandimmun Neoral) in patients with rheumatoid arthritis (RA)." | 2.69 | Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ( Battafarano, N; Fantini, F; Leoni, L; Marchesoni, A; Padula, A; Pasero, G; Ruiu, G; Taglione, E; Zeni, S, 1998) |
| "Although the SUA levels of the migraine group in the headache-free period were higher than those of the control group, the difference was not statistically significant." | 1.91 | A study of the relationship between serum uric acid levels and pain in patients with migraine. ( Altunkaynak, Y; Delen, F; Donmezler, S; Ertem, DH; Keskek, A; Kurt Sabitay, I; Olgun, H; Ozturk, M; Yazar, T, 2023) |
| "It was concluded that the insomnia was more prevalent than the sleep apnea." | 1.72 | Epidemiological studies of sleep disorder in educational community of Pakistani population, its major risk factors and associated diseases. ( Ahmad, S; Akmal, H; Ashfaq, M; Aslam, MW; Ditta, A; Jafar, K; Javed, T; Khan, MS; Khan, T; Rehman, TU; Sehgal, SA; Tahir, R; Umar, A; Waheed, A; Wajid, M, 2022) |
| "The study included 300 migraine patients and 150 healthy controls for a total of 450 individuals." | 1.62 | Evaluation of serum uric levels in migraine. ( Altunkaynak, Y; Aygün, A; Karabacak, V; Kirbaş, D; Yazar, HO; Yazar, T, 2021) |
| "Class 3 HELLP syndrome is considered a clinically significant transitional group." | 1.30 | The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. ( Blake, PG; Magann, EF; Martin, JN; May, WL; Rinehart, BK; Terrone, DA, 1999) |
| " How the adverse effects of and charges for this procedure compare with those of the standard marrow harvest is not known." | 1.29 | Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. ( Anderlini, P; Champlin, R; Chan, KW; Körbling, M; Lichtiger, B; Miller, P; Norfleet, F; Przepiorka, D; Seong, D; Sundberg, J, 1996) |
| "Tiazofurin is a novel C-nucleoside with significant antitumor activity in murine tumor models." | 1.27 | Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. ( Culham, CA; Hartshorn, JN; Haugh, LD; Krakoff, IR; McCormack, JJ; Newman, RA; Roberts, JD; Stewart, JA; Young, JA, 1987) |
| "Azosemide is a new loop diuretic which has been shown to affect solute transport proximal to the diluting segment." | 1.26 | Effects in normal subjects of long-term administration of azosemide. ( Anderson, S; Brater, C; Muckleroy, C, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (56.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Umar, A | 1 |
| Khan, MS | 1 |
| Sehgal, SA | 1 |
| Jafar, K | 1 |
| Ahmad, S | 1 |
| Waheed, A | 1 |
| Aslam, MW | 1 |
| Wajid, M | 1 |
| Rehman, TU | 1 |
| Khan, T | 1 |
| Ditta, A | 1 |
| Akmal, H | 1 |
| Ashfaq, M | 1 |
| Javed, T | 1 |
| Tahir, R | 1 |
| Altunkaynak, Y | 2 |
| Keskek, A | 1 |
| Donmezler, S | 1 |
| Yazar, T | 2 |
| Olgun, H | 1 |
| Delen, F | 1 |
| Kurt Sabitay, I | 1 |
| Ozturk, M | 1 |
| Ertem, DH | 1 |
| Yazar, HO | 1 |
| Aygün, A | 1 |
| Karabacak, V | 1 |
| Kirbaş, D | 1 |
| Saag, KG | 1 |
| Becker, MA | 1 |
| Whelton, A | 1 |
| Hunt, B | 1 |
| Castillo, M | 1 |
| Kisfalvi, K | 1 |
| Gunawardhana, L | 1 |
| Li, JJ | 1 |
| Huang, YH | 1 |
| Lin, YY | 1 |
| Li, MM | 1 |
| Chen, YF | 1 |
| Cai, RW | 1 |
| FINKELSTEIN, J | 1 |
| ESCOBAR, E | 1 |
| Ben Salem, F | 1 |
| Ben Salem, K | 1 |
| Grati, L | 1 |
| Arfaoui, C | 1 |
| Faleh, R | 1 |
| Jmel, A | 1 |
| Guerdelly, I | 1 |
| Gahbiche, M | 1 |
| Weisel, KC | 1 |
| Brugger, W | 1 |
| Kröber, SM | 1 |
| Kaiserling, E | 1 |
| Kanz, L | 1 |
| Emmerson, BT | 1 |
| Neyer, U | 1 |
| Wöss, E | 1 |
| Haller, R | 1 |
| Kröss, R | 1 |
| Anderlini, P | 1 |
| Przepiorka, D | 1 |
| Seong, D | 1 |
| Miller, P | 1 |
| Sundberg, J | 1 |
| Lichtiger, B | 1 |
| Norfleet, F | 1 |
| Chan, KW | 1 |
| Champlin, R | 1 |
| Körbling, M | 1 |
| Marchesoni, A | 1 |
| Fantini, F | 1 |
| Battafarano, N | 1 |
| Zeni, S | 1 |
| Ruiu, G | 1 |
| Padula, A | 1 |
| Taglione, E | 1 |
| Pasero, G | 1 |
| Leoni, L | 1 |
| Witlin, AG | 1 |
| Saade, GR | 1 |
| Mattar, F | 1 |
| Sibai, BM | 1 |
| Martin, JN | 1 |
| Rinehart, BK | 1 |
| May, WL | 1 |
| Magann, EF | 1 |
| Terrone, DA | 1 |
| Blake, PG | 1 |
| Bogner, G | 1 |
| Tilscher, H | 1 |
| Brater, C | 1 |
| Anderson, S | 1 |
| Muckleroy, C | 1 |
| Bosl, R | 1 |
| Shideman, JR | 1 |
| Meyer, RM | 1 |
| Buselmeier, TJ | 1 |
| von Hartitzsch, B | 1 |
| Kjellstrand, CM | 1 |
| Helgeland, A | 1 |
| Strømmen, R | 1 |
| Hagelund, CH | 1 |
| Tretli, S | 1 |
| Sullivan, FM | 1 |
| Murray, TS | 1 |
| Gaw, N | 1 |
| Langan, JJ | 1 |
| Adams-Strump, BJ | 1 |
| Roberts, JD | 1 |
| Stewart, JA | 1 |
| McCormack, JJ | 1 |
| Krakoff, IR | 1 |
| Culham, CA | 1 |
| Hartshorn, JN | 1 |
| Newman, RA | 1 |
| Haugh, LD | 1 |
| Young, JA | 1 |
| Chini, V | 1 |
| Holmes, EL | 1 |
| Gifford, RW | 1 |
| Lawlor, T | 1 |
| Wells, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout[NCT02139046] | Phase 3 | 1,790 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A participant was considered to have a gout flare if the following criteria were met:~Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare." (NCT02139046)
Timeframe: Baseline to Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.7 |
| Febuxostat IR 40 mg | 21.0 |
| Febuxostat XR 40 mg | 22.8 |
| Febuxostat IR 80 mg | 27.2 |
| Febuxostat XR 80 mg | 26.6 |
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Febuxostat IR 40 mg | 15.7 |
| Febuxostat XR 40 mg | 25.9 |
| Febuxostat IR 80 mg | 42.6 |
| Febuxostat XR 80 mg | 50.1 |
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.6 |
| Febuxostat IR 40 mg | 40.3 |
| Febuxostat XR 40 mg | 48.2 |
| Febuxostat IR 80 mg | 57.7 |
| Febuxostat XR 80 mg | 61.1 |
6 trials available for uric acid and Headache
| Article | Year |
|---|---|
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delay | 2019 |
Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Biological Availability; Blood Pressure; Chemistry, Pharma | 1998 |
Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway.
Topics: Adult; Aged; Atenolol; Blood Glucose; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; | 1986 |
Is nifedipine a suitable first-line treatment for essential hypertension in general practice?
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; | 1987 |
Experimental observations on flufenamic, mefenamic, and meclofenamic acids. IV. Toleration by normal human subjects.
Topics: Adult; Anti-Inflammatory Agents; Aspirin; Biphenyl Compounds; Blood Coagulation; Blood Urea Nitrogen | 1966 |
Ethacrynic acid alone and in combination with methyldopa in the management of mild hypertension. A report of 23 patients.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diarrhea; Drug Synergism; Ethacrynic Acid; Fe | 1970 |
19 other studies available for uric acid and Headache
| Article | Year |
|---|---|
Epidemiological studies of sleep disorder in educational community of Pakistani population, its major risk factors and associated diseases.
Topics: Adult; Epidemiologic Studies; Female; Headache; Humans; Male; Migraine Disorders; Pakistan; Prevalen | 2022 |
A study of the relationship between serum uric acid levels and pain in patients with migraine.
Topics: Antioxidants; Cross-Sectional Studies; Female; Headache; Humans; Male; Migraine Disorders; Prospecti | 2023 |
Evaluation of serum uric levels in migraine.
Topics: Adult; Biomarkers; Female; Headache; Headache Disorders; Humans; Male; Middle Aged; Migraine Disorde | 2021 |
The association of uric acid with leukoaraiosis.
Topics: Aged; Aged, 80 and over; Alcohol Drinking; Asian People; Cognitive Dysfunction; Cross-Sectional Stud | 2017 |
[CONTROLLED SURVEY IN GERIATRICS. II. COMPARATIVE STUDY OF 4 THERAPEUTIC AGENTS].
Topics: Androgens; Blood Chemical Analysis; Cell- and Tissue-Based Therapy; Cholesterol; Estrogens; Fatigue; | 1964 |
[Risk factors for eclampsia: a case-control study].
Topics: Adult; Analysis of Variance; Aspartate Aminotransferases; Case-Control Studies; Creatinine; Eclampsi | 2003 |
Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders.
Topics: Aged; Anemia, Hemolytic; Biomarkers, Tumor; Diagnosis, Differential; Disease Progression; Fatal Outc | 2004 |
Regimen of indomethacin therapy in acute gouty arthritis.
Topics: Adult; Creatine; Female; Gout; Headache; Humans; Indomethacin; Male; Middle Aged; Nausea; Urea; Uric | 1967 |
[Headache and EEG changes caused by acetate and bicarbonate dialysis].
Topics: Acetates; Acid-Base Equilibrium; Adult; Bicarbonates; Electroencephalography; Headache; Humans; Naus | 1983 |
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
Topics: Adolescent; Adult; Alkaline Phosphatase; Analgesics; Blood Transfusion, Autologous; Bone Marrow Tran | 1996 |
Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia.
Topics: Abruptio Placentae; Adolescent; Adult; Blood Pressure; Eclampsia; Female; Headache; Humans; Logistic | 1999 |
The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification.
Topics: Aspartate Aminotransferases; Birth Weight; Cesarean Section; Eclampsia; Female; Fetal Death; Headach | 1999 |
[Spinal complaints of hyperuricemic patients].
Topics: Back Pain; Female; Gout; Headache; Humans; Male; Neurologic Manifestations; Osteoarthritis; Pain; Sp | 1976 |
Effects in normal subjects of long-term administration of azosemide.
Topics: Diet, Sodium-Restricted; Diuretics; Drug Evaluation; Headache; Humans; Nausea; Potassium; Renin; Sod | 1979 |
Effects and complications of high efficiency dialysis.
Topics: Barbiturates; Blood Urea Nitrogen; Body Weight; Calcium; Creatinine; Edema; Headache; Humans; Hypote | 1975 |
Letter: Chronic interstitial nephritis: analgesic "abuse", hyperuricemia.
Topics: Analgesics; Chronic Disease; Female; Headache; Humans; Nephritis, Interstitial; Substance-Related Di | 1975 |
Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Topics: Adult; Aged; Allopurinol; Antimetabolites, Antineoplastic; Creatine Kinase; Drug Administration Sche | 1987 |
[Arterial hypertension with convulsive seizures in a patient with right kidney hypoplasia and gout attacks and with a probable gouty kidney].
Topics: Electrocardiography; Gout; Headache; Heart; Humans; Hydronephrosis; Hypertension; Kidney; Kidney Dis | 1973 |
Metabolic hazards of fasting.
Topics: Adult; Anemia; Autoanalysis; Blood Cell Count; Blood Proteins; Blood Urea Nitrogen; Body Weight; Chl | 1969 |